

# LncRNA EPIC1 downregulation mediates hydrogen peroxide-induced neuronal cell injury

Jian Sun<sup>1,\*</sup>, Jinyu Zheng<sup>2,\*</sup>, Ya Li<sup>3,\*</sup>, Ming Yan<sup>1</sup>, Ping Li<sup>4</sup>, Lili Ma<sup>5</sup>

<sup>1</sup>Department of Anesthesiology, Huai'an Maternity and Child Healthcare Hospital, Yangzhou University Medical School, Huai'an, China

<sup>2</sup>Department of Neurosurgery, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China

<sup>3</sup>The Central Lab, North District, Suzhou Municipal Hospital Affiliated to Nanjing Medical University, Suzhou, China

<sup>4</sup>Department of Radiotherapy and Oncology, Affiliated Kunshan Hospital to Jiangsu University, Kunshan, China

<sup>5</sup>Department of Anesthesiology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer of Hospital Nanjing Medical University, Nanjing, China

\*Equal contribution

**Correspondence to:** Lili Ma, Ping Li; email: [yanghaikou1977@163.com](mailto:yanghaikou1977@163.com), [drlipingkuns@163.com](mailto:drlipingkuns@163.com)

**Keywords:** neuronal cells, hydrogen peroxide, lncRNA EPIC1, MYC

**Received:** September 7, 2019

**Accepted:** November 19, 2019

**Published:** December 8, 2019

**Copyright:** Sun et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## ABSTRACT

**Excessive oxidative stress causes neuronal cell injury. Long non-coding RNA (LncRNA) EPIC1 (Lnc-EPIC1) is a MYC-interacting LncRNA. Its expression and potential functions in hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)-stimulated neuronal cells are studied. In SH-SY5Y neuronal cells and primary human neuron cultures, H<sub>2</sub>O<sub>2</sub> downregulated Lnc-EPIC1 and key MYC targets (*Cyclin A1*, *CDC20* and *CDC45*). Ectopic overexpression of Lnc-EPIC1 increased expression of MYC targets and significantly attenuated H<sub>2</sub>O<sub>2</sub>-induced neuronal cell death and apoptosis. Contrarily, Lnc-EPIC1 siRNA potentiated neuronal cell death by H<sub>2</sub>O<sub>2</sub>. MYC knockout by CRISPR/Cas9 method also facilitated H<sub>2</sub>O<sub>2</sub>-induced SH-SY5Y cell death. Significantly, MYC knockout abolished Lnc-EPIC1-induced actions in H<sub>2</sub>O<sub>2</sub>-stimulated neuronal cells. Together, these results suggest that Lnc-EPIC1 downregulation mediates H<sub>2</sub>O<sub>2</sub>-induced neuronal cell death.**

## INTRODUCTION

Neurons in the central nerve system (CNS) are vulnerable to reactive oxygen species (ROS) overproduction and excessive oxidative injury. It is possibly due to the high rate of oxygen consumption, enrichment of polyunsaturated fatty acids and defective Nrf2 cascade in neurons [1–5]. Excessive oxidative stress will induce profound neuronal cell injury, serving as a key pathogenesis mechanism of neurodegenerative diseases [1–4]. Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), produced during the redox process, has been widely utilized to treat cultured neurons and neuronal cells *in vitro*, mimicking oxidative injury [6–8]. H<sub>2</sub>O<sub>2</sub> overproduction can induce profound lipid peroxidation, DNA breaks, protein damage and eventually neuronal cell death and apoptosis [7, 9, 10].

Understanding the molecular mechanisms of H<sub>2</sub>O<sub>2</sub>-induced neuronal cell death is vital for developing possible intervention strategies.

Long non-coding RNAs (LncRNAs) are traditionally considered as transcriptional noise. Recently, there are growing literatures showing that LncRNAs are key regulators of almost all cellular and physiological processes [11, 12]. LncRNAs' functions in CNS and neuronal cells are still largely elusive [13, 14]. The transcription factor MYC is vital for the transcription and expression of key genes of cell survival in neuronal cells [15, 16]. The activity of MYC is mainly controlled by transcriptional and posttranscriptional mechanisms [17, 18]. Wang et al., recently demonstrated that LncRNA EPIC1

(epigenetically-induced LncRNA1, “Lnc-EPIC1”) directly associates to MYC [19].

Lnc-EPIC1 (ENSG00000224271)’s binding to MYC occurs at Lnc-EPIC1’s 129-283 nucleotide region [19]. Lnc-EPIC1 silencing will lead to the inhibited occupancy of MYC to its target genes (*CDC20*, *CDC45* and *CCNA2*) [19], suppressing their expression [19]. Furthermore, MYC knockout abolished Lnc-EPIC1-induced actions [19]. Recently, Zhang et al., have shown that Lnc-EPIC1 protected human osteoblasts from dexamethasone-induced cell death via interacting with MYC [20]. Studies have also shown that Lnc-EPIC1-MYC association promoted survival and growth of human lung cancer cells and cholangiocarcinoma cells [21, 22]. Considering that MYC is important for neuronal survival [15, 16] and Lnc-EPIC1 is vital for its functions [19–22], we here tested expression and potential functions of Lnc-EPIC1 in hydrogen peroxide ( $H_2O_2$ )-treated neuronal cells.

## RESULTS

### $H_2O_2$ downregulates Lnc-EPIC1 in neuronal cells

In order to study the potential effect of LncRNA EPIC1 (Lnc-EPIC1) in neuronal cells, differentiated SH-SY5Y neuronal cells were treated with  $H_2O_2$ . Expression of Lnc-EPIC1 was tested by qPCR assay using the described primers [21, 22]. Its level was normalized to *U6 RNA*. As demonstrated,  $H_2O_2$  treatment (300  $\mu$ M) time-dependently decreased Lnc-EPIC1 level in SH-SY5Y cells (Figure 1A). Its levels reduced to  $83.51 \pm 6.56\%$ ,  $61.79 \pm 3.31\%$ ,  $43.34 \pm 7.72\%$ ,  $37.84 \pm 2.10\%$  of control after 2h, 4h, 8h and 16h of  $H_2O_2$  treatment, respectively (Figure 1A). Further, in a dose-dependent manner  $H_2O_2$  downregulated Lnc-EPIC1 in SH-SY5Y cells (Figure 1B). Lnc-EPIC1 downregulation was significant following 100-300  $\mu$ M of  $H_2O_2$  treatment (Figure 1B). At the lowest concentration (50  $\mu$ M)  $H_2O_2$  failed to significantly alter Lnc-EPIC1 expression ( $P > 0.05$  vs. “Ctrl”, Figure 1B).

Lnc-EPIC1 directly interacts with MYC, essential for MYC function and expression of key MYC targets [19, 21, 22]. qPCR assay results, in Figure 1C, demonstrated that mRNA levels of the MYC targets, *Cyclin A1*, *CDC20* and *CDC45* [19, 21, 22], were significantly downregulated after  $H_2O_2$  (100/300  $\mu$ M) treatment in SH-SY5Y cells. Cyclin A1, CDC20 and CDC45 protein levels were decreased as well (Figure 1D), where MYC mRNA and protein expression were unchanged (Figure 1C and 1D).

In the primary human neuronal cultures,  $H_2O_2$  treatment (300  $\mu$ M, 16h) significantly downregulated Lnc-EPIC1

expression ( $28.24 \pm 1.21\%$  of control, Figure 1E). mRNA and protein expression levels of MYC targets, Cyclin A1, CDC20 and CDC45, were also downregulated (Figure 1F and 1G). MYC expression was again unchanged by  $H_2O_2$  (Figure 1F and 1G). These results show that  $H_2O_2$  downregulates Lnc-EPIC1 and MYC targets in neuronal cells, indicating a functional activity of Lnc-EPIC1 in  $H_2O_2$ -induced neuronal cytotoxicity.

### Ectopic overexpression of Lnc-EPIC1 inhibits $H_2O_2$ -induced neuronal cytotoxicity

In order to test the potential function of Lnc-EPIC1 in  $H_2O_2$ -induced neuronal cytotoxicity, a lentiviral Lnc-EPIC1-expression construct was transfected to SH-SY5Y cells. Three stable SH-SY5Y cell lines (“Lnc-EPIC1-OE-1/-2/-3”) were established following puromycin selection (see Methods). qPCR assay was performed to show that Lnc-EPIC1 levels were significantly elevated in the Lnc-EPIC1-OE cells, with/without  $H_2O_2$  treatment (Figure 2A). Expression of key MYC targets, including CDC20 and CDC45, were dramatically increased in Lnc-EPIC1-OE cells (Figure 2B and 2C). Further,  $H_2O_2$ -induced downregulation of CDC20 and CDC45 was reversed by Lnc-EPIC1 overexpression (Figure 2B and 2C).

Significantly,  $H_2O_2$ -induced cell viability (CCK-8 OD) reduction (Figure 2D) and cell death (medium LDH release, Figure 2E) were largely attenuated by Lnc-EPIC1 overexpression (Figure 2D and 2E).  $H_2O_2$  induced significant apoptosis activation in control SH-SY5Y cells, evidenced by caspase-3 activation (Figure 2F) and single-strand DNA (“ssDNA”) accumulation (Figure 2G), which were significantly attenuated in Lnc-EPIC1-OE cells (Figure 2F and 2G). Furthermore,  $H_2O_2$ -induced mitochondrial depolarization, evidenced by JC-1 green fluorescence accumulation, was largely inhibited with Lnc-EPIC1 overexpression (Figure 2H).


In primary human neuron cultures, transfection of the lentiviral Lnc-EPIC1-expression construct (“LV-Lnc-EPIC1”) significantly increased Lnc-EPIC1 expression, even after  $H_2O_2$  stimulation (Figure 2I).  $H_2O_2$ -induced neuronal death, reflected by CCK-8 OD reduction (Figure 2J) and medium LDH release (Figure 2K), was significantly attenuated by LV-Lnc-EPIC1 (Figure 2I–2K). Collectively, these results show that ectopic overexpression of Lnc-EPIC1 attenuates  $H_2O_2$ -induced neuronal cytotoxicity.

### Lnc-EPIC1 siRNA potentiates $H_2O_2$ -induced neuronal cell death


Since Lnc-EPIC1 overexpression protected neuronal cells from  $H_2O_2$  (see Figure 2), Lnc-EPIC1 silence should then potentiate  $H_2O_2$ -induced neuron injury. To

test this hypothesis, two different Lnc-EPIC1 siRNAs (“EPIC1-siRNA1/2”), with non-overlapping sequences [19, 21, 22], were transfected to SH-SY5Y cells. As demonstrated, each of the applied EPIC1-siRNA (at 500 nM) further decreased Lnc-EPIC1 level in H<sub>2</sub>O<sub>2</sub>-treated SH-SY5Y cells (Figure 3A). MYC targets, including

*CDC20* and *CDC45*, were downregulated by EPIC1-siRNA (Figure 3B and 3C). There levels went further decreased following H<sub>2</sub>O<sub>2</sub> treatment (Figure 3B and 3C). *CDC20* and *CDC45* protein levels were also decreased in Lnc-EPIC1-silenced SH-SY5Y cells after H<sub>2</sub>O<sub>2</sub> treatment (Figure 3D).




**Figure 1. H<sub>2</sub>O<sub>2</sub> downregulates Lnc-EPIC1 in neuronal cells.** SH-SY5Y cells (A–D) or the primary human neuron cultures (E–G) were treated with hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>, 50–300 μM), cells were further cultured for indicated time periods, expression of Lnc-EPIC1 (A, B and E, vs. *U6 RNA*) and listed mRNAs (C and F, vs. *GAPDH*) were tested by qPCR assay. Listed proteins in total cell lysates were tested by Western blotting assay (D and G). Listed proteins were quantified, with the values normalized to Tubulin (D and G). “Ctrl” stands for untreated control cells (same for all Figures). “LDH%” stands for medium LDH ratio, indicating cell death (same for all Figures). Bars stand for mean ± standard deviation (SD, n=5). \* *P* < 0.05 vs. “Ctrl” cells. Experiments in this figure were repeated three times, and similar results were obtained.



**Figure 2. Ectopic overexpression of Lnc-EPIC1 inhibits H<sub>2</sub>O<sub>2</sub>-induced neuronal cytotoxicity.** Stable SH-SY5Y cells with the lentiviral Lnc-EPIC1-expression construct (three lines, “Lnc-EPIC1-OE-1/-2/-3”) or the vector control cells (“Vector”) were treated with hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>, 300 μM), cells were further cultured for indicated time, expression of Lnc-EPIC1 (A) and listed mRNAs (B and C) were tested by qPCR assay; Cell survival (by the CCK-8 assay, D), death (by the LDH assay, E) and apoptosis (by the caspase-3 activity, ssDNA ELISA and JC-1 staining assays, F–H) were tested. The primary human neuron cultures were infected with the lentivirus with Lnc-EPIC1 construct (“LV-Lnc-EPIC1”) or empty vector (“Vector”) for 48h, treated with hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>, 300 μM) for applied time, Lnc-EPIC1 expression (I), neuronal survival (by the CCK-8 assay, J) and death (by the LDH assay, K) were tested. Bars stand for mean ± standard deviation (SD, n=5). \* *P* < 0.05 vs. “Ctrl” treatment of “Vector” cells. # *P* < 0.05 vs. H<sub>2</sub>O<sub>2</sub> treatment of “Vector” cells. Experiments in this figure were repeated three times, and similar results were obtained. Bar= 100 μm (H).

Importantly, in SH-SY5Y cells, H<sub>2</sub>O<sub>2</sub>-induced viability (CCK-8 OD) reduction (Figure 3E), cell death (medium LDH release, Figure 3F) and apoptosis (increases in caspase-3 activity and ssDNA accumulation, Figure 3G and 3H) were significantly potentiated by Lnc-EPIC1 siRNAs (Figure 3E–3H). Lnc-EPIC1 siRNA alone also induced significant SH-SY5Y cell death and apoptosis (Figure 3E–3H).

In the primary human neuronal cultures, siRNA-mediated knockdown of Lnc-EPIC1 (by “EPIC1-siRNA1”, see Figure 3I) augmented H<sub>2</sub>O<sub>2</sub>-induced viability reduction (Figure 3J) and cell death (Figure 3K). Collectively, H<sub>2</sub>O<sub>2</sub>-induced neuronal cytotoxicity is exacerbated by Lnc-EPIC1 silencing, further supporting that Lnc-EPIC1 downregulation mediates H<sub>2</sub>O<sub>2</sub>-induced cytotoxicity in the neuronal cells.



**Figure 3. Lnc-EPIC1 siRNA potentiates H<sub>2</sub>O<sub>2</sub>-induced neuronal cell death.** SH-SY5Y cells (A–H) or the primary human neuron cultures (I–K) were transfected with applied Lnc-EPIC1 siRNA (“EPIC1-siRNA1/2”, 100-500 nM) or scramble control siRNA (“scr-siRNA”, 500 nM) for 48h, then treated with/without hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>, 300 μM), cells were further cultured for indicated time, expression of Lnc-EPIC1 (A and I) and listed mRNAs (B and C) were tested by qPCR assay; Expression of listed proteins was tested by Western blotting assay (D); Cell viability (by the CCK-8 assay, E and J), cell death (by the LDH assay, F and K) and apoptosis (by the caspase-3 activity and ssDNA ELISA, G and H) were tested. Listed proteins were quantified, with the values normalized to Tubulin (D). Bars stand for mean ± standard deviation (SD, n=5). \* *P* < 0.05 vs. “Ctrl” treatment in “scr-siRNA” cells. # *P* < 0.05 vs. H<sub>2</sub>O<sub>2</sub> treatment of “scr-siRNA” cells. Experiments in this figure were repeated three times, and similar results were obtained.

## MYC knockout abolishes Lnc-EPIC1-induced actions in H<sub>2</sub>O<sub>2</sub>-stimulated neuronal cells

If MYC is the primary target of Lnc-EPIC1 in neuronal cells, Lnc-EPIC1 should be ineffective in the MYC-knockout cells. To test this hypothesis, CRISPR/Cas9 strategy was applied. Two different lenti-CRISPR/Cas9-MYC-KO-GFP constructs, targeting non-overlapping DNA sequence of MYC, were transfected to SH-SY5Y neuronal cells. Via FACS-mediated GFP sorting and puromycin selection, stable monoclonal cells were established (“MYC-KO-L1/L2”), showing completely depleted *MYC mRNA* (Figure 4A). Consequently, mRNA expression of MYC targets, including *Cyclin A1*, *CDC20* and *CDC45*, were significantly downregulated (Figure 4A, left panel). Additionally, cyclin A1, CDC20 and CDC45 protein levels were largely reduced in MYC-KO SH-SY5Y cells (Figure 4A, right panel).

MYC-KO cells presented with decreased cell viability and increased cell death, when compared to the control cells with lenti-CRISPR control construct (“Cas9-C”) (Figure 4B and 4C). Importantly, MYC-KO cells were more vulnerable to H<sub>2</sub>O<sub>2</sub>, by showing significantly enhanced viability reduction and death versus control cells (Figure 4B and 4C). Therefore, MYC-KO cells presented with similar phenotypes to the Lnc-EPIC1-silenced cells (Figure 3). Notably, MYC-KO did not significantly change Lnc-EPIC1 expression in SH-SY5Y cells with/without H<sub>2</sub>O<sub>2</sub> stimulation (Figure 4D).

Further studies demonstrated that in MYC KO cells (“MYC-KO-L1”), Lnc-EPIC1 overexpression (by “LV-Lnc-EPIC1”) or silencing (by “EPIC1-siRNA1”) failed to change H<sub>2</sub>O<sub>2</sub>-induced cytotoxicity (Figure 4E and 4F). Although both LV-Lnc-EPIC1 or the siRNA altered Lnc-EPIC1 expression in H<sub>2</sub>O<sub>2</sub>-stimulated neuronal cells (Figure 4G). Similar results were also obtained in the “MYC-KO-L2” cells (Data not shown). Therefore, MYC knockout abolished Lnc-EPIC1-induced actions in H<sub>2</sub>O<sub>2</sub>-stimulated SH-SY5Y cells, suggesting that MYC is the primary target of Lnc-EPIC1.

## DISCUSSION

LncRNAs are involved in regulating almost all key cellular behaviors, by functioning as molecular signals, guides, scaffolds, enhancers or microRNA spongers, and altering gene transcription and/or functions [11, 12, 23]. Moreover, LncRNAs are important for genomic imprinting, cell cycle progression, cell survival, differentiation and development [11, 12, 23]. A growing number of studies have reported that aberrant LncRNA expression is detected in neuronal cells and human brain, participating in the pathogenesis of brain and even in neurodegenerative diseases [14]. LncRNA can function

as an endogenous RNA (ceRNA) for various miRNAs to inhibit or promote neuronal cell apoptosis. For example, Li et al., have shown that LncRNA KCNQ10T1 promoted SH-SY5Y neuronal cell apoptosis by sponging miR-296 and upregulating Bax [24]. In ischemic stroke LncRNA SNHG6 (small nucleolar RNA host gene 6) promoted neuronal cell apoptosis by inhibiting miR-181c but upregulating its target Bim [25]. Here we tested the involvement of Lnc-EPIC1 in H<sub>2</sub>O<sub>2</sub>-induced neuronal cell death.

LncRNA-mediated regulation on MYC transcriptional activity is largely unknown until recently [19]. MYC by itself is unable to form a homodimer nor binding to DNA. Certain LncRNAs interact directly with proteins and can influence the structural state and activity of these proteins [14]. Wang et al., have demonstrated that Lnc-EPIC1 regulates MYC’s occupancy on several key MYC target genes, including *Cyclin A1*, *CDC20* and *CDC45* [19]. By directly binding to double-strand DNA, Lnc-EPIC1 functions as the “guide” RNA to promote expression of MYC targets [19]. Furthermore, MYC-MAX association can also be facilitated by Lnc-EPIC1 [19]. Here our evidence suggest that Lnc-EPIC1 is also vital for the survival of neuronal cells.


We here reported a new mechanism of Lnc-EPIC1 in promoting neuronal cell survival via directly interacting with MYC, and Lnc-EPIC1 is important for MYC function in neuronal cells. In both SH-SY5Y cells and primary neuron cultures, forced overexpression of Lnc-EPIC1 significantly increased mRNA and protein expression of key MYC targets, including *Cyclin A1*, *CDC20* and *CDC45*. Contrarily, their levels were significantly reduced by siRNA-mediated silencing of Lnc-EPIC1. Importantly, Lnc-EPIC1 was decreased in H<sub>2</sub>O<sub>2</sub>-treated SH-SY5Y cells and primary neuronal cultures. Therefore, H<sub>2</sub>O<sub>2</sub> downregulates Lnc-EPIC1 to inhibit MYC functions, which could be an important mechanism responsible for H<sub>2</sub>O<sub>2</sub>-induced neuronal cell death.

A number of recent data have implied that Lnc-EPIC1, by directly interacting with MYC, promotes survival of human cells [20–22]. However, Zhao et al., have reported that it inhibited osteosarcoma cell survival by inducing MEF2D ubiquitination [26]. Results from this study support that Lnc-EPIC1 exerts neuronal protective functions. We show that Lnc-EPIC1 downregulation mediated H<sub>2</sub>O<sub>2</sub>-induced neuronal cytotoxicity. Importantly, ectopic overexpression of Lnc-EPIC1 using a lentiviral construct significantly attenuated H<sub>2</sub>O<sub>2</sub>-induced neuronal cytotoxicity. On the contrary, siRNA-mediated silencing of Lnc-EPIC1 potentiated neuronal cell death and apoptosis by H<sub>2</sub>O<sub>2</sub>. Lnc-EPIC1 siRNA alone was cytotoxic to neuronal cells as well. Thus,

targeting Lnc-EPIC1 could be a novel strategy for neuronal protection against oxidative injury.

MYC is a transcription factor regulating expression of a wide variety of genes of cell survival. In the present study, we show that MYC KO by CRISPR/Cas9 method induced neuronal cell death and apoptosis. MYC KO also intensified H<sub>2</sub>O<sub>2</sub>-induced neuronal cytotoxicity.

Importantly, neither Lnc-EPIC1 overexpression nor Lnc-EPIC1 siRNA was functional in MYC-KO cells. These evidence indicated that MYC is the primary target of Lnc-EPIC1 in neuronal cells. Further insight studies are necessary to explore the interaction between Lnc-EPIC1 and MYC as well as their functions in neuronal cells. In summary, we conclude that Lnc-EPIC1 downregulation mediates H<sub>2</sub>O<sub>2</sub>-induced neuronal cell death.



**Figure 4. MYC knockout abolishes Lnc-EPIC1-induced actions in H<sub>2</sub>O<sub>2</sub>-stimulated neuronal cells.** Expression of listed mRNAs and proteins in the stable SH-SY5Y cells with the lenti-CRISPR/Cas9-MYC-KO-GFP constructs (“MYC-KO-L1/L2”) or the control construct (“Cas9-C”) as well as in the parental control cells (“Pare”) were shown (A). Above cells were treated with/without hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>, 300 μM) for the applied time, cell viability (by CCK-8 assay, B) and death (by LDH assay, C) were examined; Lnc-EPIC1 levels were tested by qPCR assay (D). “MYC-KO-L1” cells were transfected with lentiviral Lnc-EPIC1 construct (“LV-Lnc-EPIC1”) or Lnc-EPIC1 siRNA-1 (“EPIC1-siRNA1”, 500 nM) for 48h, followed by hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>, 300 μM) stimulation for the applied time, cell viability (E), cell death (F) and Lnc-EPIC1 expression (G) were tested. Listed proteins were quantified, with the values normalized to Tubulin (A). Bars stand for mean ± standard deviation (SD, n=5). \* P < 0.05 vs. “Ctrl” treatment of “Pare” cells (A–D). \* P < 0.05 vs. “Ctrl” treatment (E–G). # P < 0.05 vs. H<sub>2</sub>O<sub>2</sub> treatment of “Pare” cells (A–C). Experiments in this figure were repeated three times, and similar results were obtained.

## MATERIALS AND METHODS

### Reagents

H<sub>2</sub>O<sub>2</sub>, puromycin, polybrene, fetal bovine serum (FBS) and other cell culture reagents were provided by Sigma-Aldrich Co. (St. Louis, MO). Antibodies were purchased from Cell Signaling Technology Co. (Shanghai, China). mRNA primers and sequences were synthesized by Genechem (Shanghai, China). All the transfection reagents were purchased from Invitrogen-Thermo Fisher Co. (Shanghai, China).

### SH-SY5Y cells

Human neuronal SH-SY5Y cells (from Dr. Gao [27]) were cultured in DMEM plus 10% FBS. Before H<sub>2</sub>O<sub>2</sub> treatment, SH-SY5Y cells were cultured for 10 days in retinoic acid (RA, 10 μM)-containing complete DMEM medium, followed by another five days culture in serum-free DMEM with BDNF (50 ng/mL) and glutamine (2 mM).

### Primary human neuron cultures

The primary human neuron cultures were provided by Dr. Zhang [28]. Briefly, the normal fetal brains were digested and filtered. The dissociated neurons were centrifuged and resuspended in MEM medium with the described supplements [29]. Neurons were plated in poly-L-lysine-coated six-well plates. Astrocytes were abandoned [29]. Neuron cultures were grown for eight days (day *in vitro* 8, DIV8) before any further experiments. The protocols of using human cells were approved by the Ethics Committee of authors' institutions.

### Quantitative real-time PCR assay (qPCR)

Following the applied treatment, the TRIzol reagents (Promega) was applied to extract total cellular RNA. The Fast-Start Universal SYBR Green Master mix (Roche) was used for the qPCR. Melting curve analysis was performed to calculate the product melting temperature. qPCR quantification was through 2<sup>-ΔCt</sup> method using the following formula: 2<sup>-(Ct of target gene - Ct of reference gene)</sup>. The data presented were normalized to *GAPDH* transcripts. mRNA primers for *MYC*, *Cyclin A1*, *CDC20*, and *CDC45* [19] and Lnc-EPIC1 [22] were synthesized by Genechem (Shanghai, China). Lnc-EPIC1 expression was normalized to *U6 RNA*.

### Western blotting assay

For each treatment, 40 μg protein lysates were separated by 10% SDS-PAGE gels, transferred to PVDF blots.

After blocking in 10% non-fat milk, the blots were probed with the appropriate primary antibodies, followed by incubation in the HRP-conjugated secondary antibodies. The blots were visualized by the ECL system (Sigma). Quantification of the band intensity was performed via using the Image J software.

### Ectopic Lnc-EPIC1 overexpression

The pLenti6-GFP-puro expression vector with Lnc-EPIC1 sequence ("LV-EPIC1") was provided by Dr. Zhang [22], transfected to SH-SY5Y cells (in polybrene-containing medium) through Lipofectamine 2000. Stable cells were selected via puromycin (2.0 μg/mL). Three stable SH-SY5Y cell lines with LV-EPIC1 were established, named as "Lnc-EPIC1-OE1/2/3". qPCR assay was performed to verify Lnc-EPIC1 overexpression. Control cells were transfected with empty vector ("Vector"). For the primary human neuron cultures, LV-EPIC1 was directly transfected to neurons, and no puromycin-mediated selection was performed.

### Cell viability assay

Neuronal cells were seeded in the 96-well plates (2 × 10<sup>4</sup> cells/cm<sup>2</sup>). Following treatment, cell viability was examined by the Cell Counting Kit-8 (CCK-8, Dojindo, Japan). CCK-8 optical density (OD) values at 550 nm were recorded.

### LDH assay

Following the applied treatment, lactate dehydrogenase (LDH) release to the conditional medium of dying cells was tested by a two-step LDH detection kit (Takara, Tokyo, Japan). Medium LDH was normalized to total LDH.

### Lnc-EPIC1 siRNA

Two Lnc-EPIC1 siRNAs, 5'-CCUUCAGACUGUCU UUGAA-3' ("EPIC1-siRNA1") and 5'-GCUUUCU CUCGGAAACGUG-3' ("EPIC1-siRNA2"), were utilized [21, 22]. SH-SY5Y cells or the primary neurons were seeded in the six well tissue culture plates (2 × 10<sup>4</sup> cells/cm<sup>2</sup>), transfected with Lnc-EPIC1 siRNA or the scramble control siRNA ("scr-siRNA") using the Lipofectamine RNAiMAX Reagent for 48h. Lnc-EPIC1 knockdown was verified by qPCR assay.

### Caspase-3 activity assay

The caspase-3 activity assay was described in detail elsewhere [30].

## ssDNA ELISA assay

Single strand DNA (ssDNA) contents were measured as a characteristic marker of cell apoptosis. In brief, thirty  $\mu\text{g}$  cell lysates per treatment were analyzed by the ssDNA ELISA (Roche, Basel, Switzerland) to quantify DNA fragmentations. The ssDNA ELISA absorbance values were recorded at 405 nm.

## JC-1 assay of mitochondrial depolarization

JC-1, a fluorescence dye, can form green monomers and aggregate in mitochondria in stressed cells with mitochondrial depolarization [31]. Following the applied  $\text{H}_2\text{O}_2$  treatment, neuronal cells were first stained with JC-1 (10  $\mu\text{g}/\text{mL}$ ), washed and tested immediately via a fluorescence spectrofluorometer at 550 nm. The representative JC-1 images, integrating the green (at 550 nm) and red (at 625 nm) fluorescence wavelength were presented.

## MYC knockout

MYC small guide RNA (sgRNA) (sgRNA-1: 5'-GCCGATTTCTACTGCGACG-3' [22] or sgRNA-2: 5'-CTATGACCTCGACTACGACT-3') was packed into the lenti-CRISPR-GFP vector (From Dr. Zhang [22]). By using Lipofectamine 2000 each of the two constructs was individually transfected to SH-SY5Y cells. GFP-positive cells were FACS sorted. After culturing for another 3 weeks, cells were distributed to six well plates, followed by genotyping of depleted MYC. The monoclonal cells were further selected by puromycin for seven days. Control cells were transfected with lenti-CRISPR/Cas9-GFP construct with scramble sgRNA ("Cas9-c").

## Statistical analysis

Data were expressed as the mean  $\pm$  standard deviation (SD). Statistical analyses among different groups were performed by the one-way analysis of variance (ANOVA) with Scheffe's test using SPSS18.0 software (SPSS Inc., Chicago, IL). The two-tailed paired T tests (Excel 2007) were calculated to compare significance between two groups. Values of  $P < 0.05$  were considered statistically significant. Experiments were repeated at least three times.

## Abbreviations

CNS: central nerve system; FBS: fetal bovine serum;  $\text{H}_2\text{O}_2$ : hydrogen peroxide; LDH: lactate dehydrogenase; LncRNA: long non-coding RNA; Lnc-EPIC1: LncRNA EPIC1; qPCR: quantitative real-time PCR assay; OD: optical density; ssDNA: single strand DNA; SD: standard deviation.

## AUTHORS CONTRIBUTIONS

All listed authors designed the study, performed the experiments and the statistical analysis, and wrote the manuscript. All authors have read the manuscript and approved the final version.

## CONFLICTS OF INTEREST

The authors declare no conflict of interests.

## FUNDING

This study was supported by the National Natural Science Foundation (81773192, 81472786), Foundation of tumor clinical and basic research team (KYC005), Jiangsu Province Youth Medical Talents Project (QNRC2016527), Jiangsu Province "333 Project" Research Projects (2016-III-0367); Kunshan Science and Technology Program (KS180570), Jiangsu University Clinical Medical Science and Technology Development Fund (JLY20180012), Huai'an Natural Science Research Program (HAB201824), and by Natural Science Foundation of Jiangsu Province (BK20171248).

## REFERENCES

1. Okazawa H, Ikawa M, Tsujikawa T, Kiyono Y, Yoneda M. Brain imaging for oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. *Q J Nucl Med Mol Imaging*. 2014; 58:387–97. PMID:[25366710](https://pubmed.ncbi.nlm.nih.gov/25366710/)
2. Allen CL, Bayraktutan U. Oxidative stress and its role in the pathogenesis of ischaemic stroke. *Int J Stroke*. 2009; 4:461–70. <https://doi.org/10.1111/j.1747-4949.2009.00387.x> PMID:[19930058](https://pubmed.ncbi.nlm.nih.gov/19930058/)
3. Fatokun AA, Stone TW, Smith RA. Oxidative stress in neurodegeneration and available means of protection. *Front Biosci*. 2008; 13:3288–311. <https://doi.org/10.2741/2926> PMID:[18508433](https://pubmed.ncbi.nlm.nih.gov/18508433/)
4. Trushina E, McMurray CT. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. *Neuroscience*. 2007; 145:1233–48. <https://doi.org/10.1016/j.neuroscience.2006.10.056> PMID:[17303344](https://pubmed.ncbi.nlm.nih.gov/17303344/)
5. Bell KF, Al-Mubarak B, Martel MA, McKay S, Wheelan N, Hasel P, Márkus NM, Baxter P, Deighton RF, Serio A, Bilican B, Chowdhry S, Meakin PJ, et al. Neuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2. *Nat Commun*. 2015; 6:7066. <https://doi.org/10.1038/ncomms8066> PMID:[25967870](https://pubmed.ncbi.nlm.nih.gov/25967870/)

6. Xu Y, Gao YW, Yang Y. SC79 protects dopaminergic neurons from oxidative stress. *Oncotarget*. 2017; 9:12639–48.  
<https://doi.org/10.18632/oncotarget.23538>  
PMID:[29560097](https://pubmed.ncbi.nlm.nih.gov/29560097/)
7. Chen L, Xu B, Liu L, Luo Y, Yin J, Zhou H, Chen W, Shen T, Han X, Huang S. Hydrogen peroxide inhibits mTOR signaling by activation of AMPKalpha leading to apoptosis of neuronal cells. *Lab Invest*. 2010; 90:762–73.  
<https://doi.org/10.1038/labinvest.2010.36>  
PMID:[20142804](https://pubmed.ncbi.nlm.nih.gov/20142804/)
8. Chen X, Zhang Q, Cheng Q, Ding F. Protective effect of salidroside against H2O2-induced cell apoptosis in primary culture of rat hippocampal neurons. *Mol Cell Biochem*. 2009; 332:85–93.  
<https://doi.org/10.1007/s11010-009-0177-3>  
PMID:[19554425](https://pubmed.ncbi.nlm.nih.gov/19554425/)
9. Lee HJ, Cho HS, Park E, Kim S, Lee SY, Kim CS, Kim DK, Kim SJ, Chun HS. Rosmarinic acid protects human dopaminergic neuronal cells against hydrogen peroxide-induced apoptosis. *Toxicology*. 2008; 250:109–15.  
<https://doi.org/10.1016/j.tox.2008.06.010>  
PMID:[18644421](https://pubmed.ncbi.nlm.nih.gov/18644421/)
10. Zhang L, Yu H, Sun Y, Lin X, Chen B, Tan C, Cao G, Wang Z. Protective effects of salidroside on hydrogen peroxide-induced apoptosis in SH-SY5Y human neuroblastoma cells. *Eur J Pharmacol*. 2007; 564:18–25.  
<https://doi.org/10.1016/j.ejphar.2007.01.089>  
PMID:[17349619](https://pubmed.ncbi.nlm.nih.gov/17349619/)
11. Ulitsky I. Evolution to the rescue: using comparative genomics to understand long non-coding RNAs. *Nat Rev Genet*. 2016; 17:601–14.  
<https://doi.org/10.1038/nrg.2016.85>  
PMID:[27573374](https://pubmed.ncbi.nlm.nih.gov/27573374/)
12. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. *Nat Rev Genet*. 2014; 15:7–21.  
<https://doi.org/10.1038/nrg3606> PMID:[24296535](https://pubmed.ncbi.nlm.nih.gov/24296535/)
13. Wang A, Wang J, Liu Y, Zhou Y. Mechanisms of Long Non-Coding RNAs in the Assembly and Plasticity of Neural Circuitry. *Front Neural Circuits*. 2017; 11:76.  
<https://doi.org/10.3389/fncir.2017.00076>  
PMID:[29109677](https://pubmed.ncbi.nlm.nih.gov/29109677/)
14. Andersen RE, Lim DA. Forging our understanding of lncRNAs in the brain. *Cell Tissue Res*. 2018; 371:55–71.  
<https://doi.org/10.1007/s00441-017-2711-z>  
PMID:[29079882](https://pubmed.ncbi.nlm.nih.gov/29079882/)
15. Wartiovaara K, Barnabe-Heider F, Miller FD, Kaplan DR. N-myc promotes survival and induces S-phase entry of postmitotic sympathetic neurons. *J Neurosci*. 2002; 22:815–24.  
<https://doi.org/10.1523/JNEUROSCI.22-03-00815.2002>  
PMID:[11826111](https://pubmed.ncbi.nlm.nih.gov/11826111/)
16. Okano HJ, Park WY, Corradi JP, Darnell RB. The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival. *Genes Dev*. 1999; 13:2087–97.  
<https://doi.org/10.1101/gad.13.16.2087>  
PMID:[10465786](https://pubmed.ncbi.nlm.nih.gov/10465786/)
17. Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. *Signal Transduct Target Ther*. 2018; 3:5.  
<https://doi.org/10.1038/s41392-018-0008-7>  
PMID:[29527331](https://pubmed.ncbi.nlm.nih.gov/29527331/)
18. Brägelmann J, Böhm S, Guthrie MR, Mollaoglu G, Oliver TG, Sos ML. Family matters: how MYC family oncogenes impact small cell lung cancer. *Cell Cycle*. 2017; 16:1489–98.  
<https://doi.org/10.1080/15384101.2017.1339849>  
PMID:[28737478](https://pubmed.ncbi.nlm.nih.gov/28737478/)
19. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S; Cancer Genome Atlas Research Network, Xie W, Yang D. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. *Cancer Cell*. 2018; 33:706–720.e9.  
<https://doi.org/10.1016/j.ccell.2018.03.006>  
PMID:[29622465](https://pubmed.ncbi.nlm.nih.gov/29622465/)
20. Zhang XY, Shan HJ, Zhang P, She C, Zhou XZ. lncRNA EPIC1 protects human osteoblasts from dexamethasone-induced cell death. *Biochem Biophys Res Commun*. 2018; 503:2255–62.  
<https://doi.org/10.1016/j.bbrc.2018.06.146>  
PMID:[29959919](https://pubmed.ncbi.nlm.nih.gov/29959919/)
21. Li Y, Cai Q, Li W, Feng F, Yang L. Long non-coding RNA EPIC1 promotes cholangiocarcinoma cell growth. *Biochem Biophys Res Commun*. 2018; 504:654–59.  
<https://doi.org/10.1016/j.bbrc.2018.08.174>  
PMID:[30205958](https://pubmed.ncbi.nlm.nih.gov/30205958/)
22. Zhang B, Lu HY, Xia YH, Jiang AG, Lv YX. Long non-coding RNA EPIC1 promotes human lung cancer cell growth. *Biochem Biophys Res Commun*. 2018; 503:1342–48.  
<https://doi.org/10.1016/j.bbrc.2018.07.046>  
PMID:[30029875](https://pubmed.ncbi.nlm.nih.gov/30029875/)
23. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. *Nat Rev Genet*. 2009; 10:155–59.  
<https://doi.org/10.1038/nrg2521> PMID:[19188922](https://pubmed.ncbi.nlm.nih.gov/19188922/)
24. Li MM, Liu XH, Zhao YC, Ma XY, Zhou YC, Zhao YX, Liu XY. Long noncoding RNA KCNQ1OT1 promotes apoptosis in neuroblastoma cells by regulating miR-

- 296-5p/Bax axis. FEBS J. 2019. [Epub ahead of print].  
<https://doi.org/10.1111/febs.15047>  
PMID:[31433907](https://pubmed.ncbi.nlm.nih.gov/31433907/)
25. Zhang X, Liu Z, Shu Q, Yuan S, Xing Z, Song J. LncRNA SNHG6 functions as a ceRNA to regulate neuronal cell apoptosis by modulating miR-181c-5p/BIM signalling in ischaemic stroke. *J Cell Mol Med*. 2019; 23:6120–30.  
<https://doi.org/10.1111/jcmm.14480>  
PMID:[31334597](https://pubmed.ncbi.nlm.nih.gov/31334597/)
26. Zhao W, Zhang D, Qin P, Zhang J, Cui X, Gao J, Wang J, Li J. Long non-coding RNA EPIC1 inhibits viability and invasion of osteosarcoma cells by promoting MEF2D ubiquitylation. *Int J Biol Macromol*. 2019; 128:566–73.  
<https://doi.org/10.1016/j.ijbiomac.2019.01.156>  
PMID:[30703420](https://pubmed.ncbi.nlm.nih.gov/30703420/)
27. Zhao LP, Ji C, Lu PH, Li C, Xu B, Gao H. Oxygen glucose deprivation (OGD)/re-oxygenation-induced in vitro neuronal cell death involves mitochondrial cyclophilin-D/P53 signaling axis. *Neurochem Res*. 2013; 38:705–13.  
<https://doi.org/10.1007/s11064-013-0968-5>  
PMID:[23322110](https://pubmed.ncbi.nlm.nih.gov/23322110/)
28. Jing D, Yinzhu L, Jinjing P, Lishuang L, Guozhuan Z. Targeting ninjurin 2 by miR-764 regulates hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)-induced neuronal cell death. *Biochem Biophys Res Commun*. 2018; 505:1180–88.  
<https://doi.org/10.1016/j.bbrc.2018.09.184>  
PMID:[30318119](https://pubmed.ncbi.nlm.nih.gov/30318119/)
29. Kaushal V, Dye R, Pakavathkumar P, Foveau B, Flores J, Hyman B, Ghetti B, Koller BH, LeBlanc AC. Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation. *Cell Death Differ*. 2015; 22:1676–86.  
<https://doi.org/10.1038/cdd.2015.16> PMID:[25744023](https://pubmed.ncbi.nlm.nih.gov/25744023/)
30. Petit A, Kawarai T, Paitel E, Sanjo N, Maj M, Scheid M, Chen F, Gu Y, Hasegawa H, Salehi-Rad S, Wang L, Rogaeva E, Fraser P, et al. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. *J Biol Chem*. 2005; 280:34025–32.  
<https://doi.org/10.1074/jbc.M505143200>  
PMID:[16079129](https://pubmed.ncbi.nlm.nih.gov/16079129/)
31. Brooks MM, Neelam S, Fudala R, Gryczynski I, Cammarata PR. Lenticular mitoprotection. Part A: monitoring mitochondrial depolarization with JC-1 and artifactual fluorescence by the glycogen synthase kinase-3β inhibitor, SB216763. *Mol Vis*. 2013; 19:1406–12. PMID:[23825920](https://pubmed.ncbi.nlm.nih.gov/23825920/)